Results 211 to 220 of about 136,781 (306)

Quinoxaline–Triazole Hybrids: Exploring the Impact of Substituent Architecture on Cytotoxic Potency and Receptor Interaction

Chemistry &Biodiversity, Volume 23, Issue 11, November 2026.
A series of title compounds was synthesized, with 6e and 6k exhibiting the lowest IC50 values against MCF‐7, HeLa, and HepG2 cancer cell lines. Molecular docking and dynamics revealed strong binding to the adenosine A1 receptor (ΔG = –9.02 and –9.24 kcal/mol).
Bangar Reddy Vancha, Mandapalli Sreeshitha, Shaik Farheen Banu, Kamala Prasad Vasikarla, Satyanarayana Swamy Vyshnava, Mukhriddin Makhkamov, Parthiban Marimuthu, Jamoliddin Razzokov, Aminul Islam, Peddiahgari Vasu Govardhana Reddy   +9 more
wiley   +1 more source

Experimental assessment of computationally nominated small molecules targeting the YAP-TEAD interface in Hippo pathway-altered mesothelioma cell models. [PDF]

Front Oncol
Weiss GJ, Loftus JC, Mallery DW, Tran NL.   +3 more
europepmc   +1 more source

Essential Oils of Argyreia capitiformis (Poir.) Ooststr. and Argyreia nasirii D.F. Austin: Chemical Analysis and Biological Activities

Chemistry &Biodiversity, Volume 23, Issue 11, November 2026.
Essential oils of Argyreia capitiformis and Argyreia nasirii display clearly distinct chemical and biological profiles. A. capitiformis is dominated by sesquiterpene hydrocarbons, particularly (E)‐caryophyllene, and shows cytotoxicity against HepG2, SK‐LU‐1, and MCF‐7 cells. In contrast, A.
Tran Thi Ngoc Hanh, Nguyen Thi Thu Hien, Pham Van Huyen, Nguyen Huu Huong Duyen, Phan Nha Hoa, Tran Kim Diep, Nguyen Thi Dieu Thuan, Nguyen Huu Toan Phan   +7 more
wiley   +1 more source

RETRACTED: Ibrahim et al. Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity. <i>Pharmaceuticals</i> 2020, <i>13</i>, 393. [PDF]

Pharmaceuticals (Basel)
Ibrahim TS, Hawwas MM, Malebari AM, Taher ES, Omar AM, O'Boyle NM, McLoughlin E, Abdel-Samii ZK, Elshaier YAMM.   +8 more
europepmc   +1 more source

Meroterpenoids Produced by Fungi: Occurrence, Structural Diversity, and Biological Activity (An Update: February 2020 to December 2025)

Chemistry &Biodiversity, Volume 23, Issue 11, November 2026.
This review firstly summarizes the update of meroterpenoids from February 2020 to December 2025 by applying a new classification method based on twelve key non‐terpene precursors. ABSTRACT Meroterpenoids are a class of hybrid natural products, biosynthesized from terpenoid fragments and non‐terpenoid precursors, exhibiting a wide range of biological ...
Yuqian Tang, Jinqin Wei, Zhao Jiang, Yingming Luo, Yan Zhou, Jiafan Yang, Hui Cui   +6 more
wiley   +1 more source

6‑Chloropyridinyl Benzoate Fragments as Selective Anti-Melanoma Scaffolds Triggering ROS-Mediated Mitochondrial Apoptosis. [PDF]

ACS Omega
La Monica G, Restivo I, Bono A, Alamia F, Tocco D, Attanzio A, Lauria A, Martorana A.   +7 more
europepmc   +1 more source

A Rare Case Report of Type II Kounis Syndrome With Literature Review: Acute Anterior ST Elevation Myocardial Infarction Following Bee Sting

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Kounis syndrome (KS), also known as allergic angina, is a rare but serious condition defined by acute coronary syndrome occurring alongside a hypersensitivity reaction. We report the case of a 42‐year‐old male smoker who developed Type II KS after a hymenoptera sting.
Sara Tarkiani, Mobina Ghajar, Mohammad Hossein Sharifi Fard, Mohammad Ghasemi Palangi, Armin Bordbar, Hassan Ahangar, Amin Ramezani   +6 more
wiley   +1 more source

Synthesis and Biological Evaluation of a Series of N-Substituted Pyruvamide 4-Allylthiosemicarbazones and Their Copper(II) Complexes: Antibacterial, Antiradical, and Antiproliferative Activities. [PDF]

Molecules
Graur I, Istrati D, Graur V, Tsapkov V, Garbuz O, Melnic E, Bourosh P, Roy J, Gulea A.   +8 more
europepmc   +1 more source

Welcoming Novelty in the Treatment of Coronary Artery Disease: FDA Approves the Use of Drug‐Coated Balloon for Angioplasty

Clinical Cardiology, Volume 49, Issue 11, November 2026.
The US FDA has approved the use of drug‐coated balloons (DCBs) for treating in‐stent restenosis, a major challenge in coronary artery disease management. The AGENT IDE Trial, a multicenter randomized study, evaluated the efficacy of the paclitaxel‐coated balloon catheter, demonstrating reduced rates of target lesion failure, myocardial infarction, and ...
Abdul Haseeb Hasan, Muhammad Ali Abid, Abubakar Nazir   +2 more
wiley   +1 more source